Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: J Thorac Oncol. 2015 Feb;10(2):232–236. doi: 10.1097/JTO.0000000000000455

Figure 3.

Figure 3

Marked regression in brain parenchymal metastases in a 46 year-old, ALK-positive lung cancer patient treated with alectinib. This patient had previously received both crizotinib and ceritinib, relapsing in the central nervous system after each agent. Axial, T1 post-gadolinium magnetic resonance images A) prior to alectinib and B) on alectinib.